Hepatopulmonary syndrome and portopulmonary hypertension

Naoki Umeda, Patrick S. Kamath

Research output: Contribution to journalArticlepeer-review

20 Scopus citations


The pulmonary complications of end-stage liver disease include hepatopulmonary syndrome and portopulmonary hypertension. The etio-pathogenesis of these conditions is as yet unclear. Hepatopulmonary syndrome is a gas exchange abnormality and usually manifests as hypoxemia secondary to intra-pulmonary vascular shunts. These shunts can be demonstrated by echocardiography using agitated saline injections, and quantitated by lung perfusion scans. Liver transplantation is the treatment of choice for hepatopulmonary syndrome, and there are no effective pharmacological therapies. Portopulmonary hypertension is a hemodynamic problem which manifests as fatigue and right sided cardiac failure. Several vasoactive agents have been used to lower mean pulmonary arterial pressures. Portopulmonary hypertension is a relative contraindication to liver transplantation.

Original languageEnglish (US)
Pages (from-to)1020-1022
Number of pages3
JournalHepatology Research
Issue number10
StatePublished - 2009


  • Hepatopulmonary syndrome
  • Portopulmonary hypertension

ASJC Scopus subject areas

  • Hepatology
  • Infectious Diseases


Dive into the research topics of 'Hepatopulmonary syndrome and portopulmonary hypertension'. Together they form a unique fingerprint.

Cite this